Szilard Kiss - 10 Jun 2024 Form 3 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Director
Signature
/s/ John Rakow, Attorney-in-Fact
Issuer symbol
ADVM
Transactions as of
10 Jun 2024
Net transactions value
$0
Form type
3
Filing time
20 Jun 2024, 16:42:12 UTC
Next filing
20 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ADVM Stock Option (Right to Buy) 10 Jun 2024 Common Stock 1,250 $30.50 Direct F1
holding ADVM Stock Option (Right to Buy) 10 Jun 2024 Common Stock 2,000 $61.50 Direct F1
holding ADVM Stock Option (Right to Buy) 10 Jun 2024 Common Stock 8,000 $54.10 Direct F1
holding ADVM Stock Option (Right to Buy) 10 Jun 2024 Common Stock 4,500 $94.50 Direct F1
holding ADVM Stock Option (Right to Buy) 10 Jun 2024 Common Stock 2,500 $14.00 Direct F2
holding ADVM Stock Option (Right to Buy) 10 Jun 2024 Common Stock 2,500 $9.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock option is fully vested and exercisable.
F2 The shares subject to the option vest in equal monthly installments over two years, such that all of the shares subject to the option shall become vested and exercisable as of August 16, 2024, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F3 50% of the shares subject to the option vested on March 25, 2024, and the remainder of the shares subject to the option vest in equal monthly installments thereafter through March 25, 2025, subject to the Reporting Person's continued service with the Issuer on each such vesting date.